💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Bayer plunges after Monsanto ordered to pay $289M in California cancer trial

Published 08/13/2018, 03:22 AM
© Reuters.  Bayer plunges after Monsanto ordered to pay $289M in California cancer trial
MON
-
BAYRY
-
  • Bayer (OTCPK:BAYRY) opens -9% in European trading following Friday's decision by a California jury ordering the company to pay nearly $290M for failing to warn a dying man that Monsanto (NYSE:MON)'s Roundup weedkiller might cause cancer.
  • Jurors unanimously found that Monsanto, whose merger with Bayer still must be approved by U.S. regulators, acted with "malice" and that Roundup and the professional grade RangerPro version contributed "substantially" to the man's terminal illness.
  • California Attorney General Xavier Becerra said Friday he was leading a coalition of five states opposing the merger based on concerns over the concentration of the seed market.
  • The $66B deal already has received approval from regulators in the European Union, Russia and Brazil, making U.S. approval one of the last major hurdles.
  • Now read: Tracking Dan Loeb's Third Point Portfolio - Q2 2018 Update


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.